Clinical Trials Logo

Clinical Trial Summary

The object of this non-randomized, prospective study is to assess the effectiveness of ablative fractional 2940 nm laser treatment of vulvar lichen sclerosus. Aim 1: To assess physical and histological changes related to vulvar lichen sclerosus before and after laser treatment. Aim 2: To evaluate participant satisfaction for laser treatment of vulvar lichen sclerosus. The results of this study will determine whether fractional 2940 nm laser is an effective treatment option for lichen sclerosus, particularly for those participants not eligible for high-dose topical steroids or who have failed prior treatment with topical steroids.


Clinical Trial Description

This will be a non-randomized, open-label, prospective study. Participants will be recruited in general and subspecialty obstetrics and gynecology clinics. Participants who meet all eligibility criteria, including providing written informed consent, will have three treatment visits and three follow-up visits in an outpatient setting. Participants will not be charged for any treatments. At each treatment visit, participants will be asked to complete questionnaires to assess their symptoms. The investigators will also take photographs of the affected area at each treatment visit. Photographs will include only the area of lichen sclerosus, such that individuals cannot be identified in the photographs. Participant photographs will be taken using the BIDMC PhotoConsult iOS application that allows providers to upload photographs to a patient's online medical record through a secure application. Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart. Prior to receiving treatment, topical 4% lidocaine anesthetic will be applied to the affected area for 20-30 minutes and then wiped away. The treatment area will be cleaned and dried of any moisture prior to treatment. The disinfected standoff with sapphire plate will then be applied to the ProFractional hand piece. Based on the biopsy results, the appropriate ablation depth will be inputted with 11% treatment density selected. Each treatment will include two passes of the laser over the affected area. - Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚. - Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚. - Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚. Participants will return for follow-up visits at 1, 3, and 6 months (months 3, 6 and 9 of the study) following the third treatment. - Follow-up visit 1, month 3 - Participants will be asked to complete questionnaires to assess outcomes. - The investigators will take photographs of the affected area. - Follow-up visit 2, month 6 - Participants will be asked to complete questionnaires to assess outcomes. - The investigators will take photographs of the affected area. - Biopsy of area with lichen sclerosus; the biopsy will be done the same way as the one that was done to diagnosis your lichen sclerosus - Follow-up visit 6, month 9 - Participants will be asked to complete questionnaires to assess outcomes. - The investigators will take photographs of the affected area. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04134494
Study type Interventional
Source Beth Israel Deaconess Medical Center
Contact
Status Active, not recruiting
Phase N/A
Start date January 1, 2020
Completion date October 7, 2022

See also
  Status Clinical Trial Phase
Completed NCT03961126 - Evaluation of Vulvar Lichen Sclerosus Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma. Phase 2
Completed NCT03686800 - The Comfort and Adherence of Rivelin® Plain Patches in Vulva Lichen Sclerosus Patients N/A
Completed NCT05147129 - Characterizing the Microbiome in Postmenopausal Women With Vulvar Lichen Sclerosus
Completed NCT02573883 - Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus Phase 3
Recruiting NCT06132919 - Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) Phase 2
Completed NCT04952961 - Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study N/A
Terminated NCT01126255 - Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus Phase 2
Recruiting NCT04951206 - Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus Phase 4
Recruiting NCT05250466 - A Comparative Study on the Efficacy of AI Temperature-controlled Radiofrequency Technology and Electrical Stimulation in the Treatment of Vulvar Leukoplakia N/A
Active, not recruiting NCT03926299 - Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus N/A
Completed NCT04148651 - The CO2RE® System for Vulvar Lichen Sclerosus N/A
Completed NCT02416531 - Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser N/A
Recruiting NCT04967170 - A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus Phase 1/Phase 2
Completed NCT05251220 - Efficacy and Safety of the Neodymium Laser in Treatment of Urogenital Tract Diseases in Women
Completed NCT01400022 - Topical 0.05% Clobetasol Propionate in Vaseline Versus UVA-1 Phototherapy in Vulvar Lichen Sclerosus N/A
Recruiting NCT06360705 - StrataMGT for the Treatment of Vulvar Lichen Sclerosus N/A
Completed NCT00757874 - Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus Phase 2
Recruiting NCT05243563 - Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone? Phase 2/Phase 3